CLINICAL_TRIALS
trial_result
· 2016-01-07
Clinical Trial Update: Safety and Efficacy Study of an Anti-CD20 Monoclonal Antibody (AME-133v) to Treat Non-Hodgkin's Lymphoma [Phase 1]
Summary
Phase 1 safety and efficacy study of AME-133v, an anti-CD20 monoclonal antibody, for Non-Hodgkin lymphoma has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Applied Molecular Evolution | Conditions: Non-Hodgkin's Lymphoma | Phase 1 | Status: COMPLETED